Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Head & Neck 1Breast 1

Conditions

Prostatic Neoplasms 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Specimen Handling 49Letrozole 42Fulvestrant 42Paclitaxel 38pembrolizumab 34Magnetic Resonance Spectroscopy 31Carboplatin 31ribociclib 26Trastuzumab 26Biopsy 26exemestane 23Anastrozole 23Capecitabine 22palbociclib 21pertuzumab 20Tamoxifen 19trastuzumab deruxtecan 18abemaciclib 18Cyclophosphamide 17Taxes 15Radiotherapy 14130-nm albumin-bound paclitaxel 12elacestrant 11Docetaxel 11sacituzumab govitecan 9olaparib 9Standard of Care 9Radiation 9Goserelin 9Gemcitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glutamate Carboxypeptidase II × Breast × 30 days × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡